TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04762667

Intervention type: PROCEDURE
Group type: OTHER
Intervention: reverse shoulder arthroplasty
Description: In our work, all patients are performs MSCT of the shoulder joint. The construction of a 3D model is carried out using the obtained data. Taking into account the individual features of the bone structure of the shoulder joint, images of the pilot wire guides, fixing screws and a resection template for the humerus are created. Holes for fixing spokes for the planned structures are also calculated.~Using a 3D printer, models of guides and a resection template are printed. During the reverse shoulder arthropalsty, instead of a standard guide, patient-specific instrumentation are used.~In the early postoperative period, all patients are performs MSCT of the shoulder joint. The obtained data are compared with the results of MSCT of the shoulder joints of patients previously operated on using the standard technique.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: reverse shoulder arthroplasty
Description: In our work, all patients are performs MSCT of the shoulder joint. The construction of a 3D model is carried out using the obtained data. Taking into account the individual features of the bone structure of the shoulder joint, images of the pilot wire guides, fixing screws and a resection template for the humerus are created. Holes for fixing spokes for the planned structures are also calculated.~Using a 3D printer, models of guides and a resection template are printed. During the reverse shoulder arthropalsty, instead of a standard guide, patient-specific instrumentation are used.~In the early postoperative period, all patients are performs MSCT of the shoulder joint. The obtained data are compared with the results of MSCT of the shoulder joints of patients previously operated on using the standard technique.
Study: NCT03203473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: YERVOY is thought to work with the body's immune system to increase the activity of T cells and cause the body to attack cancer cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: YERVOY is thought to work with the body's immune system to increase the activity of T cells and cause the body to attack cancer cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs
Study: NCT04291560

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stretching Exercise Intervention
Description: Sequential static stretching of the large skeletal muscle group 5 days per week. Each skeletal group is stretched for 20 seconds for 3 repetitions.
Study: NCT03203473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs
Study: NCT02426502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conversion to Advagraf
Description: Prograf treated patients will convert to Advagraf using a 1: 1 conversion for a period of one week. The dose will then be titrated based on tacrolimus trough levels obtained 7 days after conversion. Cyclosporine (Neoral) treated patients will initiate Advagraf 0.075 mg/kg/day, 24 hours after their last cyclosporine dose. Participants will be provided with Advagraf and instructed how to start this new medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conversion of non-immunosuppressant drugs to once daily
Description: * Conversion of anti-hypertensive medications: converted to once daily alternatives with the goal of maintaining blood pressure at the same or lower level prior to conversion.~* Conversion of all other medications: changed to once daily formulations of the same medication or a once daily alternative.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conversion to once daily MPA
Description: * Conversion to once daily MPA: Patients taking mycophenolate mofetil (MMF) will receive 1.0 gram once daily, while patients receiving Myfortic will receive 720 mg once daily.~* Conversion to once daily Myfortic: Patients prescribed proton pump inhibitors (PPIs) and MMF will be switched to equivalent dose Myfortic for a period of one month prior to conversion to once daily MPA.~* Patients taking azathioprine will be maintained on the same dose.~* Patients will be maintained on the same prednisone dose.
Study: NCT01334229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin 100 mg/d for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 6 weeks
Study: NCT01028963

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Description: pioglitazone 30 mg tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX140-B
Description: CCX140-B capsules once daily (Group C)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX140-B
Description: CCX140-B capsules once daily (Group D)
Study: NCT01525329

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: All patients will receive one cream, 5-Fluorouracil, and will be instructed to apply the cream according to the randomization schema to AKs on either the right or left side of the face/scalp once a day for 6 days prior to PDT. A baseline measurement of the tumor's ability to produce PpIX will be done by applying methyl-aminolevulinic acid (Metvixia® topical cream) to the selected AKs and using the Aurora© dosimeter. Prior to Metvixia, and again 3 hours after application, surface measurements of the PpIX fluorescence will be taken. Then, the two largest precancer lesions (one on the left side, one on the right side) will be biopsied under local anesthesia, followed by red light PDT (lasting \~8 minutes). The biopsy sites will be shielded from the light with a circular spot bandage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: All patients will receive one cream, 5-Fluorouracil, and will be instructed to apply the cream according to the randomization schema to AKs on either the right or left side of the face/scalp once a day for 6 days prior to PDT. A baseline measurement of the tumor's ability to produce PpIX will be done by applying methyl-aminolevulinic acid (Metvixia® topical cream) to the selected AKs and using the Aurora© dosimeter. Prior to Metvixia, and again 3 hours after application, surface measurements of the PpIX fluorescence will be taken. Then, the two largest precancer lesions (one on the left side, one on the right side) will be biopsied under local anesthesia, followed by red light PDT (lasting \~8 minutes). The biopsy sites will be shielded from the light with a circular spot bandage.
Study: NCT00185289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EV/DNG (Qlaira, BAY86-5027, SH T00658K)
Description: per cycle (28 days): Days 1-2: 3.0 mg EV; Days 3-7: 2.0 mg EV + 2.0 mg DNG; Days 8-24: 2.0 mg EV + 3.0 mg DNG; Days 25-26: 1.0 mg EV; Days 27-28: Placebo
Study: NCT03979391

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tear collection and lumbar punction
Description: Tear collection and lumbar punction will be performed in order to detect supernumerary oligoclonal bands
Study: NCT01495650

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored program of PA and nutritional counseling
Description: Patients receive tailored program of physical exercises and nutritional counseling during the course of adjuvant treatments (CT followed by RT, 27 weeks).
Study: NCT04032405

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CAF+CTG+i-prf
Description: combined connective tissue graft (CTG) and injectable platelet rich fibrin (i-prf) with coronally advanced flap (CAF)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAF+CTG+i-prf
Description: combined connective tissue graft (CTG) and injectable platelet rich fibrin (i-prf) with coronally advanced flap (CAF)
Study: NCT04881474

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 800 mg
Description: 30-minute lasting iv infusion of 800 mg ibuprofen diluted with 0,9% saline via intravenous route every 6 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 800 mg
Description: 30-minute lasting iv infusion of 800 mg ibuprofen diluted with 0,9% saline via intravenous route every 6 hours.
Study: NCT01221870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesetaxel once every 3 weeks
Description: Tesetaxel capsules orally once every 21 days; duration of therapy not to exceed 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesetaxel once weekly
Description: Tesetaxel capsules orally once every 7 days for 3 consecutive weeks in a 28-day cycle; duration of therapy not to exceed 12 months
Study: NCT03347110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Bimekizumab at a prespecified dose.
Study: NCT04378972

Intervention type: OTHER
Intervention: curcumin, homotaurine, vitamin D3
Description: ELISA tests on supernatants of 25 vitreous biopsies incubated with bioactive molecules at 37 ° C for 20 h. The concentration of soluble mediators was calculated from a calibration curve.

Intervention type: OTHER
Intervention: control
Description: ELISA tests on supernatants of 25 vitreous biopsies. The concentration of soluble mediators was calculated from a calibration curve.
Study: NCT02111798

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be randomly assigned to receive placebo powder in twice-daily capsules at the end of week 2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be randomly assigned to receive placebo powder in twice-daily capsules at the end of week 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion XL
Description: Participants will be randomly assigned to receive bupropion XL 150mg/day in twice-daily capsules at the end of week 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion XL
Description: Participants will be randomly assigned to receive bupropion XL 150mg/day in twice-daily capsules at the end of week 2.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Abstinence Initiation
Description: Participants will provide urine samples thrice weekly during weeks 1-6 of the study. Urine samples will be tested immediately onsite for evidence of recent cocaine exposure. Participants who do not provide 3 urine samples that test negative for cocaine by the end of week 6 will be assigned to an Abstinence Incentive condition.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Abstinence Initiation
Description: Participants will provide urine samples thrice weekly during weeks 1-6 of the study. Urine samples will be tested immediately onsite for evidence of recent cocaine exposure. Participants who do not provide 3 urine samples that test negative for cocaine by the end of week 6 will be assigned to an Abstinence Incentive condition.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relapse Prevention
Description: Participants will provide urine samples thrice weekly during weeks 1-6 of the study. Urine samples will be tested immediately onsite for evidence of recent cocaine exposure. Participants who provide 3 urine samples that test negative for cocaine will be promptly assigned to a Relapse Prevention incentive condition.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Relapse Prevention
Description: Participants will provide urine samples thrice weekly during weeks 1-6 of the study. Urine samples will be tested immediately onsite for evidence of recent cocaine exposure. Participants who provide 3 urine samples that test negative for cocaine will be promptly assigned to a Relapse Prevention incentive condition.
Study: NCT00114140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Concurrent chemoradiotherapy temozolomide given 75 mg/m\^2 daily during radiotherapy for 6 weeks.~Post-Radiation Temozolomide given 150 mg/m2 daily on days 1-5 every 28 days with cycle one beginning 28 days post-radiotherapy. In the absence of grade 3 or 4 adverse events, a single dose escalation to 200 mg/m2/day could be attempted for cycle 2 and, if tolerated, that dose should continue for all subsequent cycles. Cycles were repeated every 28 days (+/- 2 days) for a total of 12 cycles.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: One treatment of 1.8 Gy given daily, 5 days per week (over 6 weeks) for a total dose of 54.0 Gy.
Study: NCT01368497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir and peginterferon
Description: Entecavir 0.015 mg/kg/day (up to 0.5 mg maximum daily dose) once daily for 48 weeks and Peginterferon alfa-2a 180 µg/1.73m2 subcutaneously once weekly for 40 weeks beginning 8 weeks after entecavir monotherapy).
Study: NCT01803698

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training in the use of IOM charts
Study: NCT03531775

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Upright MRI
Description: Participants will be scanned using an upright MRI in sitting/standing position and supine position. They will also be scanned in supine position using a conventional MRI.
Study: NCT02662387

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External nasal dilator (END)
Description: Applying External nasal dilator as adjuvant to high flow oxygen

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula (HFNC)
Description: Non-invasive positive pressure ventilation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High flow nasal cannula (HFNC)
Description: Non-invasive positive pressure ventilation
Study: NCT01000051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Starting daily dose 50 mg orally on empty stomach (1 hour before or 2 hours after a meal) for 8 weeks. East Asians start at 25 mg daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once a day, orally for 8 weeks.
Study: NCT00947622

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Transcranial Direct current stimulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Transcranial Direct current stimulation
Study: NCT04439240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FGFR Inhibitor AZD4547
Description: Given PO
Study: NCT01772498

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: heart rate variability biofeedback
Study: NCT00710502

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transvaginal NOTES cholecystectomy
Description: Under general anesthesia, patients will undergo Transvaginal NOTES cholecystectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transvaginal NOTES cholecystectomy
Description: Under general anesthesia, patients will undergo Transvaginal NOTES cholecystectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy
Description: Under general anesthesia, patients will undergo standard Laparoscopic cholecystectomy
Study: NCT02644967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMO-2125
Description: Drug: IMO-2125 Intratumoral injection administered as 9 doses on Weeks 1, 2, 3, 5, 8, 11, 17, 23, and 29.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 4 doses administered intravenously at a dose of 3 mg/kg over 90 minutes on Weeks 2, 5, 8, and 11.
Study: NCT03667339

Intervention type: PROCEDURE
Intervention: Direct Anterior Total Hip Arthroplasty
Description: Direct Anterior Total Hip Arthroplasty

Intervention type: PROCEDURE
Intervention: Direct Anterior Total Hip Arthroplasty
Description: Direct Anterior Total Hip Arthroplasty
Study: NCT03814694

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CRHP Diet
Description: Dietary macronutrient composition of 30 E% from carbohydrate, 30 E% from protein and 40 E% from fat

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CD Diet
Description: Dietary macronutrient composition of 50 E% from carbohydrate, 17 E% from protein and 33 E% from fat
Study: NCT02765997

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Unmanipulated UCB
Description: Unmanipulated UCB infusion given on Day 0. All patients will receive the same conditioning and immunoprophylaxis for the prevention of acute and chronic GVHD, previously demonstrated to offer the best outcomes in recipients of partially HLA matched UCB. Standard supportive care, including the use of Neupogen \[G-CSF\] and prophylactic anti-bacterial, protozoal, viral and fungal agents, will also be prescribed. Supportive care will be modified throughout the transplant course at the treating physician's judgement.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SR-1 UCB
Description: SR-1 UCB infusion given on Day 0. All patients will receive the same conditioning and immunoprophylaxis for the prevention of acute and chronic GVHD, previously demonstrated to offer the best outcomes in recipients of partially HLA matched UCB. Standard supportive care, including the use of Neupogen \[G-CSF\] and prophylactic anti-bacterial, protozoal, viral and fungal agents, will also be prescribed. Supportive care will be modified throughout the transplant course at the treating physician's judgement.
Study: NCT00471679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethanol
Study: NCT02323412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin (Amoksicillintrihydrat)
Description: Amoxicillin tablets 750 mg 1x3 for 100 days (oral intake).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets 1x3 for 100 days (oral intake).
Study: NCT01560975

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SENSIMED Triggerfish®
Description: Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours
Study: NCT01400477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMXB-A-SR
Description: Experimental Study Drug: 3-2, 4 dimethoxybenzylidene anabaseine sustained release (DMXB-A-SR)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study: NCT03582462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IONIS FXI-LRx
Description: Ascending single and multiple doses of IONIS FXI-LRx by subcutaneous (SC) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator
Study: NCT01228201

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate continuous training
Description: Three training sessions per week in a total of 12 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic interval training
Description: Three training sessions per week in a total of 12 weeks
Study: NCT02816736

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LCZ696
Description: Subjects previously taking no or low-dose ACEI or ARB, or who have an eGFR \< 30 mL/min/1.73m²: starting dose of LCZ696 = 50 mg po BID.~Subjects taking an ARB at greater than low dose: starting dose of LCZ696 = 100 mg po BID.~Subjects taking an ACEI at greater than low dose: starting dose of LCZ696 = 100 mg po BID.~\* At Investigator discretion, study drug may be started at the low dose if there are any concerns regarding tolerability.~Dose adjustments will be performed every 2 weeks by doubling the dose of LCZ696 up to the target max dose of 200 mg po BID as tolerated.~The doses of LCZ696 are 50mg (one low-dose (50mg) tablet), 100mg (one high-dose (100mg) tablet), and 200mg (two high-dose (100mg) tablets.) These doses are equivalent to 24/26 mg, 49/51 mg, and 97/103 mg commercial Entresto™, respectively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valsartan
Description: Subjects previously taking no or low-dose ACEI or ARB, or who have an eGFR \< 30 mL/min/1.73m²: the starting dose of valsartan = 40 mg po BID.~Subjects taking an ARB at greater than low dose: starting dose of valsartan = 80 mg po BID.~Subjects taking an ACEI at greater than low dose: starting dose of valsartan = 80 mg po BID.~\* At Investigator discretion, study drug may be started at the low dose if there are any concerns regarding tolerability.~Dose adjustments will be performed every 2 weeks by doubling the dose of valsartan up to the target maximum dose of 160 mg po BID, as tolerated.~The doses of valsartan are 40mg (one low-dose (40mg) tablet), 80mg (one high-dose (80mg) tablet), and 160mg (two high-dose (80mg) tablets).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LCZ696 placebo
Description: LCZ696 placebo tablets will be supplied to match the low-dose (50mg) and high-dose (100mg) active LCZ696 tablets. Dosing for LCZ696 placebo will mirror dosing for active valsartan (the same number of low or high-dose tablets will be given.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valsartan placebo
Description: Valsartan placebo tablets will be supplied to match the low-dose (40mg) and high-dose (80mg) active valsartan tablets. Dosing for valsartan placebo will mirror dosing for active LCZ696 (the same number of low or high-dose tablets will be given.)